The purpose of the present invention is to provide spermatozoa having high motility. The present invention is a composition for treating sperm that comprises a mesenchymal stem cell culture supernatant. The composition for spermatozoa treatment of the present invention is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Furthermore, mesenchymal stem cells in the mesenchymal stem cell culture supernatant comprised in the composition for treating sperm are preferably derived from adipose tissue, derived from umbilical cord tissue, or derived from bone marrow tissue.
TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (Japan)
ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Shimada,masayuki
Kusama,kazuya
Abstract
Provided is a preparation with which it is possible to promote normal decidualization of the endometrium. An agent for promoting or improving decidualization of the endometrium, the agent containing an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared. Furthermore, an agent for promoting or improving cell fusion, the agent containing an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared.
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
3.
METHOD FOR PREPARING CELLS FOR TREATING DISEASES, METHOD FOR PROMOTING MIGRATION ABILITY OF CELLS, METHOD FOR PROMOTING PROLIFERATION ABILITY OF CELLS, AND CELLS OBTAINED BY THESE METHODS
An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.
The purpose of the present invention is to provide a culture medium for immature eggs that is excellent in quality and safety and that is capable of efficiently maturing immature eggs with respect to immature eggs for vitro maturation-in vitro fertilization-embryo transfer method (IVM-IVF). The present invention is a composition that is for treating immature eggs and/or embryos (fertilized eggs) and that contains a serum-free mesenchymal stem cell culture medium. The treatment composition is suitably used as an immature egg culture agent, an embryo (fertilized egg) culture agent, an implantation adjuvant, an embryo transfer liquid or an implantation rate improver.
The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for treating sperm that comprises medium for mesenchymal stem cells. This composition for treating sperm is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for treating sperm is preferably a serum-free medium.
The purpose of the present invention is to provide a preparation that is effective for maintaining or increasing a hair fibrous structural protein. Provided are a composition for maintaining or increasing a fibrous structural protein, a composition for maintaining or increasing skin elasticity, a composition for improving hair quality, and a composition for promoting the production of collagen, elastin, or hyaluronic acid, wherein each of the compositions contains a culture supernatant of microalgae and/or extracellular vesicles of microalgae.
This aqueous composition contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and has a pH of 6.0-9.0. The aqueous composition is housed in a dispensing container having a filter containing a hydrophilic material.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
The present invention relates to providing a novel compound, specifically a 1,3,5-triazine derivative and salt thereof, which has a suitable ultraviolet absorption action, and to an ultraviolet absorbent and external skin agent using the same. The present invention is the 1,3,5-triazine derivative or salt thereof represented by general formula (I), etc. (In the general formula, G1, G2, and G3each independently represent hydrogen, a straight or branched chain alkyl group, etc. having 1-12 carbon atoms which may be substituted, or -X-Z-Y. However, at least two of G1, G2, and G3may be -X-Z-Y, which may be identical or different from each other. X is O, N, or S. Y is a sulfonic acid group, a hydroxyl group, or a carboxyl group, etc., or a group corresponding to a salt thereof. Z is a straight or branched chain alkyl group, etc. having 1-8 carbon atoms. R1, R2, and R3 each independently represent a straight or branched chain alkyl group, etc. having 1-4 carbon atoms, and l, m, and n each independently represent an integer from 0 to 4.)
Provided are a cleansing composition and the like having excellent sebum cleansing properties. Specifically provided are a cleansing composition comprising components (A), (B) and (C) as mentioned below, a cleaning composition for deodorant purposes, and a method for removing an aging odor by cleansing using a cleansing composition. (A) An anionic cleansing component. (B): A component (B1) and/or a component (B2) as mentioned below. (B1) A monoester of a C6-12 fatty acid and a C1-6 polyhydric alcohol. (B2) At least one component selected from the group consisting of fatty acid alkanolamides, coconut oil fatty acid polyoxyethylene glyceryls, and polyoxyethylene alkyl ethers. (C) A water-soluble polymer.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
The present invention pertains to an ophthalmic composition containing (A) at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 1000 to 20000 and a salt thereof, and (B) a fat-soluble component.
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention pertains to an ophthalmic composition containing (A) at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 1000 to 20000 and a salt thereof, and (B) at least one selected from the group consisting of water-soluble vitamins, amino acids, and salts thereof.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
The purpose of the present invention is to provide an external-use composition with which aroma is maintained for a long period of time after application to the skin. Another purpose of the present invention is to provide a method with which it is possible, in relation to an external-use composition, to provide sufficient fragrance after application to the skin, and to maintain the fragrance for a long period of time. The present invention is an external-use composition containing (A) a hydroxy fatty acid or a salt thereof having 10 or more carbon atoms and a hydroxy group at the 4-position or 5-position, and (B) one or more components selected from the group consisting of (b-1) 1-6-valent alkyl alcohols, (b-2) amphiphilic esters, (b-3) phenol derivatives, and (b-4) cationized polymers.
The purpose of the present invention is to provide a pharmaceutical preparation that effectively activates hair dermal papilla cells. Provided is a composition for activating hair dermal papilla cells, a composition for promoting hair growth or for hair restoration, a composition for improving hair quality, and a composition for promoting production of FGF-2, FGF-7, or VEGF, the compositions containing microalgae culture supernatant and/or microalgae extracellular vesicle.
The present invention provides a novel preparation which has an excellent lipolysis-promoting effect, an excellent visceral fat and body fat loss effect, an excellent weight loss effect, and an excellent BMI improvement effect. Another purpose of the present invention is to provide a novel preparation which has an excellent insulin resistance amelioration effect, an excellent cholesterol level reduction effect, and the like. The present invention is an internal composition which contains glyasperin B and which is used for at least one of lipolysis, fat burning, fat consumption support, BMI improvement, BMI reduction support, abdominal fat loss, visceral fat loss, body fat loss, waist circumference reduction, insulin resistance amelioration, and LDL cholesterol level reduction. The internal composition according to the present invention is preferably used by adults who have a BMI of at least 23 kg/m2but less than 30 kg/m2and adults who have a visceral fat area of at least 100 cm2.
To provide an oil-based solid composition for external use having excellent stability. An oil-based solid composition for external use is prepared that comprises: (A) an oily component with a melting point of 55° C. or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
Provided is a stable emulsion composition. Prepared is an emulsion composition comprising: (A) an oily component; (B) 40% by mass or more of one or more selected from the group consisting of polyhydric alcohols having 3 to 5 carbon atoms and polyethylene glycol; (C) one or more selected from the group consisting of polyacrylamide compounds and polyvinylpyrrolidone; (D) 0%-15% by mass of water; and (E) at least one selected from PEG -20 phytosterol, polyoxyethylene arachyl ether, glyceryl behenate, and polyglyceryl-6 octastearate.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
32 - Beers; non-alcoholic beverages
35 - Advertising and business services
43 - Food and drink services, temporary accommodation
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemicals; glue and adhesives for industrial purposes; plant
growth regulating preparations; fertilizers; ceramic
glazings; priming putty; higher fatty acids; alkaline
metals; alkaline-earth metals; non-metallic minerals;
chemical compositions for developing and printing
photographs; reagent paper [not for medical purposes];
artificial sweeteners for industrial purposes; flour and
starch for industrial purposes; plastics [raw materials];
groundwood pulp or chemical pulps for manufacturing
purposes; yeast nutrients for industrial purposes; yeast for
scientific purposes; microorganisms for scientific,
industrial or agricultural use; culture medium for
photosynthetic bacteria; cultured microorganisms (not for
medical and veterinary use); bacterial preparations, other
than for medical and veterinary use; bacteriological
preparations for acetification; bacteriological preparations
other than for medical and veterinary use; gram-negative
bacteria, escherichia coli strains, and other cultured
microorganisms (not for medical and veterinary use);
cellulolytic microorganisms (not for medical and veterinary
use). Antistatic preparations for household purposes; de-greasing
preparations for household purposes; rust removing
preparations; stain removing benzine; fabric softeners for
laundry use; laundry bleach; adhesives for affixing false
hair; laundry starch; seaweed gelatine for laundry use
[funori]; adhesives for affixing false eyelashes; breath
freshening preparations; deodorants for animals; paint
stripping preparations; shoe cream; shoe black [shoe
polish]; polishing preparations; soaps and detergents;
dentifrices; cosmetics; perfumes and flavourings for
beverages [essential oils]; perfumes and food flavourings
[essential oils]; incense; abrasive paper [sandpaper];
abrasive cloth; abrasive sand; artificial pumice stone;
polishing paper; false nails; false eyelashes. Pharmaceutical preparations; reagent paper for medical
purposes; oiled paper for medical purposes; adhesive tapes
for medical purposes; drug delivery agents in the form of
edible wafers for wrapping powdered pharmaceuticals; gauze
for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; menstruation tampons; sanitary napkins; sanitary
panties; absorbent cotton; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical use; dental materials; diapers; diaper
covers; fly catching paper; mothproofing paper; lacteal
flour for babies; dietary supplements for human beings;
dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; dietary supplements for animals; semen for
artificial insemination; stem cells for medical,
pharmaceutical or veterinary use; stem cells for
regenerative medicine, medicine or veterinary use; stem
cells (only for medical and veterinary use); diagnostic
reagents for clinical or medical laboratory use; diagnostic
media for bacteriological cultures; microorganism culture
media for medical use; cell culture media for medical or
veterinary use; serums; serotherapeutic medicines; fumigants
[only for agricultural purposes]; fungicides [only for
agricultural purposes]; rodenticides [only for agricultural
purposes]; insecticides [only for agricultural purposes];
herbicides [weedkillers]; insect-repellents [only for
agricultural purposes]; antiseptics [only for agricultural
purposes]. Finger guards for medical purposes; sanitary masks;
pacifiers for babies; ice bag pillows for medical purposes;
triangular bandages; support bandages; surgical catguts;
feeding cups for medical purposes; dropping pipettes for
medical purposes; teats; medical ice bags; medical ice bag
holders; baby bottles; nursing bottles; contraceptives,
non-chemical; artificial tympanic membranes; prosthetics or
fillings materials, not for dental use; ear plugs for
swimmers; ear plugs for sleeping; ear plugs for
soundproofing; facial equipment using ultrasonic waves for
commercial use; esthetic massage apparatus for commercial
use; medical apparatus and instruments; facial equipment
using ultrasonic waves for household purposes; electric
massage apparatus for household purposes; gloves for medical
purposes; urinals for medical purposes; bed pans; ear picks. Beer; carbonated drinks [refreshing beverages]; fruit
juices; vegetable juices [beverages]; extracts of hops for
making beer; whey beverages. Advertising and publicity services; promoting the goods and
services of others through the administration of sales and
promotional incentive schemes involving trading stamps;
business management analysis or business consultancy;
business management; marketing research or analysis;
providing information concerning commercial sales;
employment agency services; auctioneering; import-export
agencies; arranging newspaper subscriptions; shorthand
services; transcription; document reproduction; office
functions, namely filing, in particular documents or
magnetic tapes; compilation of information into computer
databases; providing business assistance to others in the
operation of data processing apparatus namely, computers,
typewriters, telex machines and other similar office
machines; reception services for visitors in buildings
[office functions]; publicity material rental; rental of
photocopying machines; providing commercial information and
advice for consumers in the choice of products and services;
providing employment information; providing information
about newspaper articles being news clipping services;
rental of vending machines; retail services or wholesale
services for foods and beverages; retail services or
wholesale services for carbonated drinks [refreshing
beverages] and non-alcoholic fruit juice beverages; retail
services or wholesale services for tea, coffee and cocoa;
retail services or wholesale services for processed food;
retail or wholesale of pharmaceutical, veterinary, sanitary
preparations and medical aids; retail services or wholesale
services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; retail services or
wholesale services for cosmetics, toiletries, dentifrices,
soaps and detergents. Providing temporary accommodation; accommodation bureaux
services [hotels, boarding houses]; providing foods and
beverages; boarding for animals; preschooler and infant care
at daycare centers; retirement home; rental of meeting
rooms; rental of facilities for exhibitions; rental of futon
and quilts; rental of pillows; rental of blankets; rental of
electric hot plates for household purposes; rental of
electric toasters for household purposes; rental of
microwave ovens for household purposes; rental of cooking
equipment for industrial purposes; rental of kitchen sinks
incorporating integrated worktops for commercial use; rental
of kitchen sinks for commercial use; rental of non-electric
cooking heaters for household purposes; rental of kitchen
sinks incorporating integrated worktops for household
purposes; rental of kitchen sinks for household purposes;
rental of dishes; rental of curtains; rental of furniture;
rental of wall hangings; rental of floor coverings; rental
of towels for hotels; rental of towels for restaurants;
rental of towels. Beauty salons; barbershops; providing bath houses; garden
tree planting; garden or flower bed care; fertilizer
spreading; weed killing; vermin exterminating [for
agriculture, aquaculture, horticulture or forestry];
landscape design; massage and therapeutic shiatsu massage;
chiropractic; moxibustion; treatment for dislocated joints,
sprain, bone fractures [judo- seifuku]; bodywork therapy;
acupuncture; providing medical information; physical
examination; dietary and nutritional guidance; animal
breeding; veterinary services; beautification for animals;
nursing care; rental of potted plants; farming equipment
rental; rental of medical apparatus and instruments; rental
of fishing equipment and instruments; rental of apparatus
and instruments for use in beauty salons or barbers' shops;
rental of lawnmowers.
21.
PROPHYLACTIC/THERAPEUTIC AGENT FOR PREGNANCY-INDUCED HYPERTENSION
NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (Japan)
MEDICAL CORPORATION SANEIKAI (Japan)
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Matsumoto Kunio
Imamura Ryu
Kato Yukio
Masuo Yusuke
Mizutani Shigehiko
Kajiyama Hiroaki
Yoshihara Masato
Abstract
The present invention addresses the problem of providing a prophylactic and/or therapeutic agent for hypertensive disorders of pregnancy, which has a physical property or a molecular weight that inhibits the passage through the placental barrier, has a pharmacological activity that mimics the original physiological function of the placenta and therefore has fewer adverse side effects, is safe for a mother body and a fetus, is stable for a long period, and can exert the efficacy thereof in vivo for a long period. The present invention is a prophylactic/therapeutic agent for pregnancy-induced hypertension, which contains aminopeptidase A (APA) as an active ingredient, the prophylactic/therapeutic agent being characterized in that the APA is bound to an immunoglobulin Fc region through a peptide linker.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Yoshihara,masato
Kajiyama,hiroaki
Enomoto,atsushi
Abstract
It has been difficult to quantify the degree of epithelial-mesenchymal transition of peritoneal mesothelial cells from cell morphology, and no biomarker specific for epithelial-mesenchymal transition of mesothelial cells has been known. Provided is a method for screening a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, the method including the following steps: (a) a step for treating mesothelial cells with a candidate substance; (b) a step for determining the expression or activity level of LRRN4 (leucine rich repeat neuronal 4) in the mesothelial cells; and (c) a step for, when the expression or activity level of LRRN4 is increased as compared with the level before the treatment, then selecting the candidate substance as a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells.
The present invention addresses the problem of controlling the skin's permeability of hyaluronic acid. Specifically, a purpose of the present invention is to provide a technology for promoting or inhibiting the skin's permeability of a specific hyaluronic acid, in a skin topical composition. Another purpose of the present invention is to provide a skin topical composition that, by controlling the skin's permeability of hyaluronic acid, provides excellent feelings of use such as feeling of moistness, feeling of plumpness, permeation feeling, skin compatibility, and feeling of wetness. To solve the problem, the present invention is a skin penetration promoter that is for (B) a hyaluronic acid having a weight average molecular weight of at least 1,000,000, a hyaluronic acid derivative, or a salt thereof, and that comprises (A) a hyaluronic acid having a weight average molecular weight of at most 600,000, a hyaluronic acid derivative, or a salt thereof. The present invention is also a skin penetration inhibitor that is for (D) a hyaluronic acid having a weight average molecular weight of at most 100,000, a hyaluronic acid derivative, or a salt thereof, and that comprises (C) a hyaluronic acid having a weight average molecular weight of at least 600,000, a hyaluronic acid derivative, or a salt thereof.
The present invention relates to an ophthalmic composition containing a Janus kinase inhibitor, the ophthalmic composition being accommodated in a container sterilized by a means other than an electron beam.
The present invention relates to an aqueous composition containing: (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof; and (B) a chelating agent.
The purpose of the present invention is to provide a medium for culture excellent in growth of mesenchymal stem cells. The present invention is a mesenchymal stem cell growth promoter containing 16:0 lysophosphatidic acid, a derivative of 16:0 lysophosphatidic acid, and/or a salt thereof. The mesenchymal stem cell growth promoter of the present invention preferably also contains 18:1 lysophosphatidic acid, a derivative of 18:1 lysophosphatidic acid, and/or a salt thereof. The present invention also includes a medium for mesenchymal stem cells that contains16:0 lysophosphatidic acid, a derivative of 16:0 lysophosphatidic acid, and/or a salt thereof.
The present disclosure addresses the problem of providing a liquid agent container that readily assumes a structure corresponding to the viscosity of a liquid agent. A liquid agent container (1) comprising: a hollow cylindrical nozzle (2) that has a discharge port (20) at the distal end thereof; a ball valve (3) that is held within the nozzle (2); and a container body (4) that is connected to the nozzle (2) and is flexible, a liquid agent (L1) being accommodated in the container body (4). The nozzle (2) has an abutment surface (21) that abuts the ball valve (3) across the circumferential direction, and a holding part (22) that holds the ball valve (3) in a state of abutting the abutment surface (21). The abutment surface (21) is provided with a groove (5) that links the discharge port (20) and a space inside the nozzle (2), the space being closer to the container body (4) than the abutment surface (21).
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Absorbent cotton; adhesive plasters; adhesive tapes for medical purposes; bandages for dressings; beverages for babies; breast-nursing pads; collyrium; cotton swabs for medical use; diaper covers; disinfectants for contact lenses; ear bandages; empty capsules for pharmaceuticals; eye drops; eyepatches for medical purposes; fly catching paper; food for babies; gauze for dressings; lacteal flour for babies; liquid bandages; medicated eye-washes; menstruation bandages; menstruation tampons; mothproofing paper; reagent paper for medical purposes; sanitary napkins; sanitary panties; solutions for contact lenses
(2) Pharmaceutical preparations; Cleaning stock solution for contact lenses that increases moisture; Rinsing, cleaning, preserving solution for contact lenses; Eyewashes that are used while wearing contact lenses; Eye drops for use while wearing contact lenses; Contact lens solutions for cleaning, disinfecting and preserving purposes; Oiled paper for medical purposes; Dental materials; Diapers; Dietary supplements for humans; Dietetic beverages adapted for medical purposes; Dietetic food adapted for medical purposes; Dietary supplements for animals; Semen for artificial insemination;
Provided is an oil-in-water external composition having excellent suppression of unpleasant odor. An oil-in-water external composition comprising (A) 5% by mass or more non-polar oil, (B) a polar oil and (C) 8% by mass or more ultraviolet scattering agent.
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
30.
COMPOSITION FOR ALLEVIATING FATIGUE OR PROMOTING RECOVERY FROM FATIGUE
The purpose of the present invention is to provide a composition that contains a component that can be used in the beverage/food field and is effective on fatigue. The present invention provides a composition for alleviating fatigue or promoting the recovery from fatigue, a composition for improving exercise capabilities, a composition for enhancing physical strength, a composition for reducing blood lactic acid level, or a composition for inhibiting lactic acidosis, which contains a globin protein decomposition product. The present invention also provides a composition for alleviating fatigue or promoting the recovery from fatigue, a composition for improving exercise capabilities, a composition for enhancing physical strength, a composition for reducing blood lactic acid level, or a composition for inhibiting lactic acidosis, which contains a tetrapeptide represented by the formula: Val-Val-Tyr-Pro.
Provided is a novel composition having excellent ultraviolet ray absorption capability In the present invention, the following is prepared: an emulsified topical composition containing (C) diethylamino hydroxybenzoyl hexyl benzoate, and (A) porous silica including an ultraviolet absorber, where the average particle diameter of the porous silica is 1.4 to 40 μm, and the ultraviolet absorber included in the (A) component is solid at 25°C; or an emulsified topical composition containing (A2) porous silica including an ultraviolet absorber and (B) a non-ionic surfactant, where the average particle diameter of the porous silica is 1.4 to 40 μm, and the porous silica includes an ultraviolet absorber that is solid at 25°C.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use [funori]; adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black [shoe polish]; polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages [essential oils]; perfumes and food flavourings [essential oils]; incense; abrasive paper [sandpaper]; abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes.
(2) Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants [only for agricultural purposes]; fungicides [only for agricultural purposes]; rodenticides [only for agricultural purposes]; insecticides [only for agricultural purposes]; herbicides [weedkillers]; insect-repellents [only for agricultural purposes]; antiseptics [only for agricultural purposes].
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use (funori); adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black (shoe polish); polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages (essential oils); perfumes and food flavourings (essential oils); incense; abrasive paper (sandpaper); abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants (only for agricultural purposes); fungicides (only for agricultural purposes); rodenticides (only for agricultural purposes); insecticides (only for agricultural purposes); herbicides (weedkillers); insect-repellents (only for agricultural purposes); antiseptics (only for agricultural purposes)
34.
METHOD FOR PRODUCING GEL-LIKE WOUND HEALING AGENT, GEL-LIKE WOUND HEALING AGENT, AND AUTOLOGOUS PLATELET-RICH PLASMA GEL PREPARATION KIT FOR WOUND HEALING
The purpose of the present invention is to provide a treatment method and therapeutic agent by which a sufficient effect can be obtained even with regard to a wound or the like for which an improvement trend is not observed with existing treatment methods. The present invention pertains to a method for producing a gel-like wound healing agent, the method comprising a feature of mixing an effective amount of a platelet-rich plasma (A), 150-300 mg/mL of an ascorbic acid solution (B), 1.0-3.0 wt% of a calcium chloride solution (C), and thrombin (D), a mixing ratio of the platelet-rich plasma (A) and the ascorbic acid solution (B) being 1.0-3.0 mL of the ascorbic acid solution (B) per 8.0 mL of the platelet-rich plasma (A), a mixing ratio of the platelet-rich plasma (A) and the calcium chloride solution (C) being 1.0-3.0 mL of the calcium chloride solution (C) per 8.0 mL of the platelet-rich plasma (A), and the amount of thrombin (D) being 500-2000 U per 8.0 mL of the platelet-rich plasma (A).
The purpose of the present invention is to provide an excellent infertility treatment with which it is possible to increase the implantation rate of an embryo (fertilized egg) by improving the uterine environment. The present invention is a uterine treatment composition containing a mesenchymal stem cell culture supernatant, and is used as a uterine environment-improving agent, an implantation aid, an embryo transplant liquid, a sperm transplantation liquid, or an implantation rate-improving agent. The mesenchymal stem cells are preferably derived from adipose tissue, umbilical cord tissue, or bone marrow tissue.
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
36.
BIOMARKER FOR USE IN PREDICTION OF OCCURRENCE OF ACNE VULGARIS, PREDICTION OF SEVERITY AND DETERMINATION OF SEVERITY
Disclosed is a biomarker for use in the prediction of the occurrence and the severity of acne vulgaris, and in the determination of the severity of acne vulgaris.
The purpose of the present invention is to provide sperm having high motility. The present invention is a sperm treatment composition that contains an exosome. A sperm treatment composition according to the present invention is used as a sperm preparation solution, a sperm diluent, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a sperm motility improving solution, or a sperm fertility maintaining solution.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The purpose of the present invention is to produce and provide a burdock seed oil-containing composition that is excellent in stability. The present invention relates to a composition containing (A) burdock seed oil and (B) triethyl citrate and containing 1 to 7.5 mass% of arctigenin derived from the component (A), and a method for producing the same.
Provided is a system for determining the possibility of glaucoma without a large-scale measurement of a myoelectric potential of the heart. This glaucoma determination system (1) comprises a processing unit (112) which acquires index data pertaining to the blood flow of a subject, determines, on the basis of the acquired index data, the possibility of glaucoma pertaining to an eyeball of the subject, and outputs information pertaining to the determined possibility of glaucoma.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
40.
THERAPEUTIC AGENT FOR RENAL DISEASE AND RENAL FUNCTION-IMPROVING AGENT
The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the cultivation of mesenchymal stem cells derived from adipose tissue, umbilical tissue, or bone marrow tissue. In addition, the mesenchymal stem cell culture supernatant is preferably obtained from the cultivation of mesenchymal stem cells in a culture medium containing at least one substance selected from the group consisting of EGF, bFGF, albumin, transferrin, and insulin.
The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
The purpose of the present invention is to provide a composition that improves conditions related to ocular blood flow by evaluating effects on ocular blood flow. Provided is a composition for improving and/or maintaining ocular blood flow, said composition containing Zingiber officinale and/or an extract thereof. Also provided are a composition for maintaining the health of vascular tissues in the ocular region, a composition for anti-aging of the ocular region, a composition for improving and/or maintaining the health of the ocular region, visual field narrowing, visual field defects or the appearance or expansion of a dark spot, and a composition for treating and/or preventing ocular circulation disorders, each composition containing the aforesaid ingredient.
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Provided is a composition comprising ginger and lutein and/or crocetin, wherein decomposition over time of the components contained in the composition is suppressed. Also provided is a method for suppressing decomposition of the composition components and a method for producing the composition. The composition comprises: (A) one or more selected from the group consisting of Zingiber officinale var. Rubra and extracts thereof; and (B) one or more selected from the group consisting of lutein and crocetin.
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
44.
SYSTEM FOR DETERMINING DEPRESSION RISK USING FUNDUS IMAGE, MACHINE LEARNING MODEL GENERATION DEVICE, DEPRESSION RISK DETERMINATION DEVICE, AND DEPRESSION RISK DETERMINATION METHOD
Provided is a depression risk determining system with which it is possible to determine the risk of depression from a fundus image. The system for determining depression risk according to the present invention comprises: a machine learning model generation device that generates a trained model for determining the risk of depression; and a depression risk determination device that determines the risk of depression by using the trained model generated by the machine learning model generation device. The machine learning model generation device includes a data acquisition unit that acquires at least inquiry data for training and a fundus image for training, and a machine learning model generation unit that generates a trained model. The depression risk determination device includes a determination data acquisition unit that acquires a fundus image used for determination, a depression risk determination unit that inputs at least the fundus image used for determination to the trained model to thereby output a prediction score indicating depression risk, and a determination result output unit that outputs the determination results of depression risk on the basis of the prediction score.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof. This ophthalmic composition has a pH of 4.0 to 6.8 and is stored in a container in which a portion of or all of the part thereof contacting this ophthalmic composition is formed from plastic.
The present invention relates to an ophthalmic composition which contains tramadol or a salt thereof and does not substantially contain a preservative agent.
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof, wherein the ophthalmic composition is accommodated in a container of which part or all of a portion coming into contact with the ophthalmic composition is formed from a plastic, and the container is subjected to a sterilization treatment by a means other than an electron beam.
The objective of the present invention is to provide a biomarker for use in determination of skin aging, comprising a protein or a fragment thereof. Alternatively, the objective of the present invention is to provide a method for determining skin aging in a subject, characterized in measuring a protein or a fragment thereof in a blood sample of the subject. Yet alternatively, the objective of the present invention is to provide a method for screening a skin aging improvement substance, characterized in studying an expression level of or a concentration change in a protein or a fragment thereof in a blood sample of a subject before and after intake of a test substance by the subject. The present invention is a biomarker for use in determination of skin aging, comprising a protein selected from the group consisting of: osteomodulin (OMD); chondroadherin (CHAD); collagen type XI alpha 2 chain (COL11A2); leucine-rich repeat-containing protein 15 (LRRC15); glycoprotein hormones alpha chain/choriogonadotropin subunit beta 3/choriogonadotropin subunit beta 7 (CGA/CGB3/CGB7); lutropin subunit beta (LHB); glycoprotein hormones alpha chain/lutropin subunit beta (CGA/LHB); and glycoprotein hormones alpha chain/follitropin subunit beta (CGA/FSHB), or a fragment thereof.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
LINK GENOMICS, INC. (Japan)
ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Katabuchi, Hidetaka
Honda, Ritsuo
Niwa, Shinichiro
Kitadai, Eri
Mizunuma, Hidemi
Arita, Harumasa
Abstract
The object of the present invention is to provide: a composition for ameliorating an unpleasant state caused by menstruation, which is effective against discomfort occurring in women in the period from the first menstruation to menopause, particularly strong discomfort occurring in young women, has been sufficiently experienced as a foodstuff and has an anti-EMT activity; and a functional food containing the composition. A composition for ameliorating an unpleasant state caused by menstruation is prepared, which comprises at least one component selected from the group consisting of black rice, cherry blossom, and extracts thereof.
A first invention pertains to an aqueous composition that contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and that is housed in a container in which all or a portion thereof in contact with the aqueous composition is formed of a resin containing a polyolefin. A second invention pertains to an aqueous composition containing (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and (B) a chelating agent.
The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of citric acid, phosphoric acid, and a salt thereof (B).
The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of edetic acid, creatinine, and a salt thereof (B).
The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.
The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a strongly unpleasant feeling felt by young females, the composition having anti-EMT activity and being commonly consumed as foodstuff; and a functional food containing said composition. The present invention prepares a composition for ameliorating an unpleasant state related to menstruation, containing plant-based polyphenol.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
METHOD FOR PREPARING CELLS FOR TREATING DISEASES, METHOD FOR PROMOTING MIGRATION ABILITY OF CELLS, METHOD FOR PROMOTING PROLIFERATION ABILITY OF CELLS, AND CELLS OBTAINED BY THESE METHODS
An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.
The present invention provides a method for evaluating the efficacy of a physical or chemical means on the treatment of myopia in vivo, the method comprising: a treatment step for applying the physical or chemical means to a myopia-induced model animal in which a signaling system associated with endoplasmic reticulum stress is activated; a measurement step for measuring a myopia-associated biomarker in the animal to which the physical or chemical treatment has been applied, after a lapse of a predetermined period of time after the treatment step; and a determination step for determining that the physical or chemical means is effective on the treatment of myopia in vivo when the following determination criterion is satisfied. The determination criterion: the amount of the change in the myopia-associated biomarker from a value before the activation of the signaling system associated with endoplasmic reticulum stress to the measured value is smaller than that in a myopia-induced model animal that has not been influenced by the physical or chemical means (i.e., a control).
The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for sperm treatment that contains medium for mesenchymal stem cells. This composition for sperm treatment is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for sperm treatment is preferably a serum-free medium.
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
The purpose of the present invention is to provide spermatozoa having high motility. The present invention is a composition for spermatozoa treatment that includes a mesenchymal stem cell culture supernatant. The composition for spermatozoa treatment of the present invention is used as a spermatozoa adjustment liquid, a spermatozoa dilution liquid, a spermatozoa preservation liquid, an artificial insemination solution, an in vitro fertilization solution, a solution for spermatozoa motility enhancement, or a solution for spermatozoa fertility retention. Furthermore, mesenchymal stem cells in the mesenchymal stem cell culture supernatant included in the composition for spermatozoa treatment are preferably derived from adipose tissue, derived from umbilical cord tissue, or derived from bone marrow tissue.
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
62.
PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION WHICH CONTAINS BENZOYL PEROXIDE
A pharmaceutical composition for external application which comprises (A) benzoyl peroxide and (B) at least one component selected from (B1) glycyrrhetinic acid and derivatives and salts thereof and (B2) allantoin does not undergo the decrease in viscosity over time and can be applied and spread smoothly on the skin.
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.
A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
64.
AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Maruyama, Shoichi
Furuhashi, Kazuhiro
Tanaka, Akihito
Karasawa, Munetoshi
Takao, Yukinari
Abstract
The present invention addresses the problem of providing a fundamental therapeutic method for renal diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Provided is an oily solid composition for external use with excellent stability. The oily solid composition for external use, containing: (A) an oily component having a melting point of 55°C or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer, is prepared.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 5/44 - GlucocorticosteroidsDrugs increasing or potentiating the activity of glucocorticosteroids
A first aspect of the present invention relates to an ophthalmic composition for suppressing the dryness of the eyes, the ophthalmic composition containing at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof. A second aspect of the present invention relates to an ophthalmic composition comprising at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof and at least one component selected from the group consisting of an antihistaminic agent, a zinc salt, tetrahydrozoline and salts thereof, hydroxyethyl cellulose and salts thereof and a polyvinyl-based polymeric compound. A third aspect of the present invention relates to an ophthalmic composition comprising at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof and menthol.
Provided is a water-in-oil composition for external use that contains ascorbic acid or a salt thereof. This prepared water-in-oil composition for external use contains: (A) at least one selected from the group consisting of ascorbic acid and an ascorbic acid salt; (B) propanediol; (C) an oil component; and (D) a silicone-based surfactant. This water-in-oil composition for external use has good stability.
A61K 8/891 - Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
A61K 8/894 - Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention is a resin container having a multilayer structure including a first layer that comes into contact with liquid content and a second layer that is in contact with the first layer from an outer side of the first layer. The first layer includes a cyclic olefin copolymer and a linear low-density polyethylene resin, and the second layer includes a low-density polyethylene resin.
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
An object of the present invention is to provide a new method for evaluating and/or screening an excellent healthcare material or pharmaceutical product based on a new concept. The present invention to solve the above object is a method for evaluating and/or screening a control agent for tissue morphology and/or tissue function, the method including: applying a test substance to a tissue or cell capable of expressing a mechanical stress signaling molecule; and evaluating expression, activity, or intracellular localization of the mechanical stress signaling molecule in the tissue or cell.
Provided is a cleaning composition that has excellent usability and makes it possible to suppress reduction in the enzymatic activity of a proteolytic enzyme or a lipolytic enzyme. According to the present invention, a cleaning composition contains (A) a higher fatty acid and/or a salt thereof, (B) a proteolytic enzyme and/or a lipolytic enzyme, (C) a polyalcohol, and (D) water. The (C) content is 25–60 mass% of the entire cleaning composition. The (D) content is 5–30 mass% of the entire cleaning composition. The cleaning composition contains glycerin and/or sorbitol as (C), and the glycerin and/or sorbitol content is 10–60 mass% of the entire cleaning composition.
Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.
The present invention provides a cleaning composition which has excellent formulation stability. A cleaning composition which contains (A) an N-acylamino acid salt, (B) an amphoteric surfactant and (C) a polyoxyethylene polyoxypropylene glycol. A cleaning composition which contains (A) an N-acylamino acid salt (excluding an N-acylalkyl taurine salt) and (a) an N-acylalkyl taurine salt, wherein: the mass ratio of the component (a) to the component (A), namely (a)/(A) is 0.5 or more; and the pH thereof is 4.0 to 5.0. A cleaning composition which contains (A) an N-acylamino acid salt (excluding an N-acylalkyl taurine salt), (a) an N-acylalkyl taurine salt and (B) an amphoteric surfactant, wherein: the mass ratio of the component (a) to the component (A), namely (a)/(A) is less than 0.5; and the pH thereof is 4.0 to 5.0.
A topical composition comprises (A) at least one polyhydric alcohol having a molecular weight of 100 to 200, and (B) at least one non-polymerizable cationic compound. The component (B) may be a compound containing a metal to be a divalent or higher cation in an aqueous solution, a basic amino acid, alkanol amine, or alkyl amine, and the component (A) may be glucose, sorbitol, fructose, xylitol, or erythritol.
The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.
The purpose of the present invention is to provide a prophylactic and/or therapeutic agent for diabetes that exerts excellent effects on diabetes occurring as a side effect of the administration of an immune checkpoint inhibitor and that can also achieve certain effects on many patients. The present invention pertains to a diabetes therapeutic agent containing mesenchymal stem cells. The prophylactic and/or therapeutic agent for diabetes according to the present invention is appropriately usable particularly for diabetes caused by an immune checkpoint inhibitor and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.
Under these circumstances, the purpose of the present invention is to provide a novel anti-inflammatory agent and a novel therapeutic agent for neurological diseases using mesenchymal stem cells. The present invention pertains to mesenchymal stem cells characterized by hyperexpressing SIRT1. The present invention also involves mesenchymal stem cells characterized by hyperexpressing BDNF. Moreover, the present invention involves an anti-inflammatory agent and a therapeutic agent for neurological diseases comprising these cells.
[Problem] To provide: a screening method for searching for an ingredient that inhibits PERK (PKPK-like endoplasmic reticulum kinase) pathway and/or ATF6 (activating transcription factor 6) pathway; and eyedrops and a composition comprising an active ingredient that inhibits myopia progression in children without inhibiting normal ocular growth (emmetropization), said active ingredient being obtained by the aforesaid screening method. [Solution] Eyedrops for inhibiting myopia progression in children, said eyedrops comprising, as an active ingredient, an inhibitor of PERK pathway and/or ATF6 pathway. A screening method for an inhibitor of myopia progression in children, said screening method comprising a step for bringing candidate substances into contact with eye-derived cells and a step for selecting a candidate substance using changes in a protein and/or a gene in PERK and/or ATF6 signaling pathways in the cells as an indicator.
[Problem] To provide: a screening method for searching for an ingredient that inhibits and treats scleral thinning; and eyedrops that comprise an active ingredient, said active ingredient being obtained by the screening method, and thus that can inhibit excessive scleral thinning to thereby treat posterior ocular disease associated with scleral thinning. [Solution] Eyedrops that comprise, as an active ingredient, an ingredient capable of simultaneously inhibiting PERK pathway and/or ATF6 pathway. A screening method for an ingredient capable of simultaneously inhibiting PERK pathway and/or ATF6 pathway, said screening method comprising a step for bringing candidate substances into contact with eye-derived cells and a step for selecting a candidate substance using effects on scleral thinning in the cells as an indicator.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.
Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.
Provided is a composition for external use on skin, which can be packed in a container easily in the production thereof and is configured such that a proper amount can be discharged upon the application onto the skin. A composition for external use on skin is produced, which has good wettability on a polyolefin resin. The composition for external use on skin is prepared, the composition for external use on skin comprising (A) at least one component selected from the group consisting of ascorbic acid and an ascorbic acid salt and (B) a lower alcohol, and the composition for external use on skin being packed in a container in which a portion or the whole of a face that comes into contact with the composition for external use on skin comprises a resin containing a polyolefin.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
LINK GENOMICS, INC. (Japan)
ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Katabuchi,hidetaka
Honda,ritsuo
Niwa,shinichiro
Kitadai,eri
Hayashi,hidemi
Arita,harumasa
Abstract
The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a very unpleasant feeling felt by young females, having anti-EMT activity, and being sufficiently experienced as foodstuff; and a functional food containing said composition. According to the present invention, a composition, which is for ameliorating an unpleasant state caused by menstruation and contains at least one selected from the group consisting of black rice, cherry, and extracts thereof, is prepared.
Provided is a very stable topical composition. A topical composition is prepared that contains (A) from 1 to 40% by mass of at least one type selected from the group consisting of ascorbic acid and salts of ascorbic acid; (B) at least 20% by mass of a diol having three carbon atoms; (C) at least one type selected from the group consisting of tocopherol, salts of tocopherol, and derivatives of tocopherol; and (D) water, wherein the mass ratio of component (D) to component (A) is from 0.5 to 5.0 and the topical composition includes less than 20% by mass of glycol ether.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of citric acid, phosphoric acid, and salts of these.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of edetic acid, creatinine, and salts of these.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of citric acid, phosphoric acid, and salts of these.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of edetic acid, creatinine, and salts of these.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
In-vitro diagnostic drugs; eye wash bactericides; eye
ointments; contact lens cleaning preparations;
pharmaceutical preparations and other preparations for
destroying vermin, fungicides, herbicides; reagent paper for
medical purposes; collyrium; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements (excluding those belonging to drugs); oiled
paper for medical purposes; adhesive tapes for medical
purposes; drug delivery agents in the form of edible wafers
for wrapping powdered pharmaceuticals; gauze for dressings;
empty capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; dietary
supplements for humans; semen for artificial insemination.
The purpose of the present invention is to provide a composition which, even if the ethanol content is relatively high, suppresses ethanol-induced drying that could occur upon application onto the skin, and which, when used, gives a good feeling. Provided is a composition for external use, which contains (A) ethanol and (B) at least one selected from the group consisting of erythritol, sorbitol, and xylitol, and has an ethanol (A) content of 32 to 85 mass%.
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
Provided is a composition for external use on the skin which is excellent in terms of use feeling and appearance. The purpose of the present invention is to provide a composition for external use on the skin which has satisfactory use feeling, that is, good slipperiness, and is reduced in coloration. The composition for external use on the skin comprises (A) at least one compound selected from the group consisting of ascorbic acid and salts of ascorbic acid, (B) at least one compound selected from the group consisting of salicylic acid, salts of salicylic acid, and derivatives of salicylic acid, and (C) a diol having three carbon atoms, the content of which is 1-50 mass%.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
In-vitro diagnostic drugs; eye wash bactericides; eye
ointments; contact lens cleaning preparations;
pharmaceutical preparations and other preparations for
destroying vermin, fungicides, herbicides; reagent paper for
medical purposes; collyrium; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements (excluding those belonging to drugs); oiled
paper for medical purposes; adhesive tapes for medical
purposes; drug delivery agents in the form of edible wafers
for wrapping powdered pharmaceuticals; gauze for dressings;
empty capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; dietary
supplements for humans; semen for artificial insemination.
The present invention provides an oil-in-water cosmetic composition. The present invention is an oil-in-water cosmetic composition which contains (A) a benzotriazole type ultraviolet absorbent, (B) one or more substances that are selected from the group consisting of silicone waxes and silica, and (C) water. With respect to this oil-in-water cosmetic composition, the average particle diameter of silica in the component (B) is 1 μm or more; and the content of the component (C) based on the total amount of this oil-in-water cosmetic composition is 50% by mass or more.
The present invention relates to an ophthalmic composition for suppressing drying of the eyes, the composition containing at least one substance selected from the group consisting of chondroitin sulfates having weight-average molecular weights of 30,000 to 50,000 and salts thereof.
